No results for ‘’
Gennex Laboratories Ltd
₹11.10
(0.98%)
Sat, 19 Sept 2026, 10:34 pm
Health Technology
Pharmaceuticals: Major
24.5KGennex Laboratories Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 14.85 | 70.63 | 64.69 | 0 | 50.04 | 36.36 | 37.69 | 57.99 | 34.43 | 47.94 | 22.43 | 56.33 | 17.71 | 12.67 | 12.25 | 24.28 | 16.65 | 22.40 | 15.12 |
| Price to book ratio | 0.51 | 0.67 | 2.20 | 0.76 | 0.91 | 0.78 | 0.56 | 0.57 | 0.47 | 0.89 | 4 | 1.98 | 1.49 | 1.17 | 0.66 | 1.25 | 2.18 | 1.24 | 2.11 | 1.47 |
| Price to sales ratio | 1.17 | 0.96 | 2.44 | 1.28 | 1.46 | 0.99 | 0.56 | 0.48 | 0.34 | 0.71 | 2.91 | 1.45 | 1.08 | 0.71 | 0.42 | 0.83 | 1.56 | 1.25 | 3.40 | 1.99 |
| Price to cash flow ratio | 0 | 76.72 | 0 | 0 | 2.88 | 10.18 | 6.27 | 0 | 53.38 | 0 | 38.72 | 0 | 18.73 | 34.85 | 0 | 0 | 19.61 | 3.28 | 0 | 0 |
| Enterprise value | 8.83Cr | 11.85Cr | 54.26Cr | 20.29Cr | 23.5Cr | 19.45Cr | 13.29Cr | 16.38Cr | 14.58Cr | 25.93Cr | 114Cr | 63.93Cr | 48.51Cr | 40.73Cr | 27.6Cr | 55.76Cr | 97.07Cr | 74.1Cr | 259Cr | 254Cr |
| Enterprise value to EBITDA ratio | 12.99 | 5.65 | 39.14 | 18.79 | 16.36 | 12.75 | 7.46 | 10.86 | 9.17 | 13.01 | 27.11 | 13.99 | 21.38 | 10.12 | 8.10 | 8.37 | 17.72 | 15.66 | 14.91 | 14.96 |
| Debt to equity ratio | 0.09 | 0.09 | 0.04 | 0.06 | 0.08 | 0.06 | 0.08 | 0.10 | 0.13 | 0.15 | 0.09 | 0.12 | 0.08 | 0.14 | 0.14 | 0.19 | 0.23 | 0.01 | 0.11 | 0.15 |
| Return on equity % | 0 | 4.62 | 3.77 | 1.22 | -2.87 | 1.68 | 1.53 | 1.60 | 0.82 | 2.59 | 8.76 | 9.20 | 2.68 | 6.81 | 5.37 | 10.77 | 9.44 | 7.95 | 10.53 | 10.16 |
Gennex Laboratories Ltd Enterprise Value
The Gennex Laboratories Ltd Enterprise Value is a key financial metric used by investors to evaluate Gennex Laboratories Ltd's valuation, profitability, and overall financial performance. Tracking the Gennex Laboratories Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Gennex Laboratories Ltd (NSE: , BSE: 531739) is currently trading at ₹11.10, with a market capitalization of ₹251.1Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Gennex Laboratories Ltd Enterprise Value is essential for fundamental analysis.
Gennex Laboratories Ltd Enterprise Value Current Value
The current Gennex Laboratories Ltd Enterprise Value stands at 254Cr.
The Gennex Laboratories Ltd Enterprise Value has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Gennex Laboratories Ltd Enterprise Value Historical Trend
The Gennex Laboratories Ltd Enterprise Value has shown the following historical trend:
- 2024: 254Cr
- 2023: 259Cr
- 2022: 74.1Cr
- 2021: 97.07Cr
- 2020: 55.76Cr
The decline in Gennex Laboratories Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.
What Gennex Laboratories Ltd Enterprise Value Indicates for Investors
The Gennex Laboratories Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Gennex Laboratories Ltd.
Gennex Laboratories Ltd Enterprise Value Analysis Summary
The Gennex Laboratories Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Gennex Laboratories Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Gennex Laboratories Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.